Farmak JSC added Nalbuk, a drug for treatment of pain syndrome, to its product portfolio. The new drug is manufactured in the form of solution for injection in 1 or 2 ml ampoule No. 5 or 1 ml syringe No. 5.
Nalbuk is developed on the basis of the active substance nalbuphine. The product is used for treatment of moderate to severe pain. In addition, Nalbuk is recommended for use as a supplementary analgesic drug, to relieve pain during pre- and postoperative period, and for childbirth anesthesia.
Taking into consideration the increased public interest in medical science, Liga.net and Farmak created a joint project that gives an idea of the current situation (and the situation over past 20 years) in the world medicine. 20 medical innovations which have been the most important in the 21st century were selected. The choice was […]
Farmak reported 2019 financial results. The performance of the Company remains at a consistently high level. According to IFRS-compliant financial statements, the amount of money spent on capital investment in 2019 was UAH 714 million, which is 14.5% more than at the end of 2018. The revenue of Farmak reached UAH 6.542 billion, net profit […]
Today, Kyiv City Clinical Hospital No. 9 and Kyiv City Children’s Clinical Hospital No. 1, where coronavirus patients are treated, have been equipped with CARDIOVIT AT-1 G2 ECG machine, DEFIGARD 4000 Defibrillator/Monitor, and IM-80 (2.0) patient monitor due to the assistance of the Zhebrivski Family Charitable Foundation. 13 medical specialists will be trai...